Vasculitis after Flu Shot;Pulmonary Toxicity Associated with Amiodarone may be Difficult to Assess;Capecitabine-Induced Severe Hypertriglyceridemia;Infliximab-Induced Lupus Erythematosus Tumidus;Ifosfamide-Induced Nonconvulsive Status Epilepticus;Seizure Activity Due to an Antiseizure Drug - Especially When Used Off-Label;Two Interesting Reviews concerning Adverse Events
Restricted accessResearch articleFirst published online April, 2006
Vasculitis after Flu Shot;Pulmonary Toxicity Associated with Amiodarone may be Difficult to Assess;Capecitabine-Induced Severe Hypertriglyceridemia;Infliximab-Induced Lupus Erythematosus Tumidus;Ifosfamide-Induced Nonconvulsive Status Epilepticus;Seizure Activity Due to an Antiseizure Drug - Especially When Used Off-Label;Two Interesting Reviews concerning Adverse Events
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.
AzzamI., TovN., EliasN., NaschitzJ.E.Amiodarone toxicity presenting as pulmonary mass and peripheral neuropathy: the continuing diagnostic challenge. Postgrad Med J.2006; 82(963): 73–75.
3.
KurtM., BabaogluM.O., YasarU., ShorbagiA., GulerN.Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother.2006; 40: 328–331.
4.
SchneiderS.W., StaenderS., SchlüterB., LugerT.A., BonsmannG.Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol.2006; 142: 115–116.
5.
KilickapS., CakarM., OnalI.K.. Nonconvulsive status epilepticus due to ifosfamide. Ann Pharmacother.2006; 40: 332–335.
6.
FlowersC.M., RacoosinJ.A., KortepeterC.Seizure activity and off-label use of tiagabine. N Eng J Med.2006; 354: 773–774.
7.
NavarroV.J., SeniorJ.R.Drug-related hepatotoxicity. N Engl J Med.2006; 354: 731–739.
8.
RiefW., AvornJ., BarskyA.J.Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med.2006; 166(2): 155–160.
